rs767870 — ADIPOR2 ADIPOR2 intron 6 variant

ADIPOR2 rs767870 — When Adiponectin's Signal Doesn't Get Through

Adiponectin is one of the body's most potent insulin-sensitizing hormones, secreted by adipose tissue and acting on the liver and muscle to reduce fat accumulation and improve glucose handling. Its actions depend entirely on two receptors: AdipoR1 and AdipoR2¹¹ AdipoR2
AdipoR2: adiponectin receptor 2, encoded by ADIPOR2 on chromosome 12p13.33. Primarily activates PPARα signaling in liver and adipose tissue, enhancing fatty acid oxidation and suppressing glucose production. rs767870 sits in intron 6 of ADIPOR2, and the G allele at this locus has been linked to impaired receptor signaling, elevated liver fat content, and increased type 2 diabetes (T2D) risk in replicated studies across European populations.

The Mechanism

ADIPOR2 encodes a seven-transmembrane receptor with intrinsic ceramidase activity that converts ceramide — a pro-apoptotic and insulin-antagonizing lipid — into the cytoprotective sphingosine 1-phosphate. When adiponectin binds AdipoR2, the receptor activates PPARα²² PPARα
PPARα: peroxisome proliferator-activated receptor alpha, a nuclear transcription factor that drives expression of fatty acid oxidation genes, particularly in liver cells, which then transcribes genes for β-oxidation, reducing ectopic fat and hepatic triglyceride output. Independently, AdipoR2 activation engages AMPK³³ AMPK
AMPK: AMP-activated protein kinase, the cell's central energy sensor; activation inhibits glucose production (gluconeogenesis) and stimulates glucose uptake to suppress hepatic glucose production.

rs767870 is located in intron 6, 20 nucleotides downstream of the codon 650 splice junction (HGVS: NM_001375363.1:c.650+20G>A). As an intronic variant, it does not alter the encoded protein, but intronic variants commonly affect splicing efficiency, mRNA stability, or the binding of intronic regulatory elements — all of which can reduce receptor abundance at the cell surface. Less functional ADIPOR2 means weaker PPARα induction per unit of circulating adiponectin, attenuating the receptor-mediated reduction of liver fat and hepatic insulin resistance.

The Evidence

The primary genetic evidence comes from a Caucasian case-control study⁴⁴ Caucasian case-control study
Vaxillaire M et al. Genetic analysis of ADIPOR1 and ADIPOR2 candidate polymorphisms for type 2 diabetes in the Caucasian population. Diabetes, 2006 of 2,876 French subjects. Among three ADIPOR2 SNPs showing nominal T2D association, rs767870 was the one replicated in an independent dataset, reaching OR 1.25 (95% CI 1.07–1.45, p=0.0051) in the pooled meta-analysis. The G allele — the minor allele at ~15% frequency in Europeans — is the risk allele.

The metabolic consequences extend beyond T2D susceptibility. A Finnish multi-cohort study⁵⁵ A Finnish multi-cohort study
Kotronen A et al. Genetic variation in the ADIPOR2 gene is associated with liver fat content and its surrogate markers in three independent cohorts. European Journal of Endocrinology, 2009 found rs767870 significantly associated with liver fat content measured by proton magnetic resonance spectroscopy (¹H-MRS) in Finnish subjects, with the association validated in two further cohorts via gamma-glutamyltransferase and fasting triglyceride levels — both accepted surrogate markers of hepatic fat. This places rs767870 in the liver-fat category alongside rs738409 (PNPLA3) and rs58542926 (TM6SF2), though with more moderate effect.

A Greek cross-sectional study⁶⁶ A Greek cross-sectional study
Halvatsiotis I et al. Genetic variation in ADIPOR2 is associated with coronary artery disease and increased ADIPOR2 expression in peripheral monocytes. Cardiovascular Diabetology, 2010 found significantly different rs767870 genotype distributions between CAD and non-CAD individuals (p=0.017), with heterozygous carriers showing worse endothelial function (lower flow-mediated dilatation) and higher intima-media thickness — early markers of atherosclerotic burden.

The evidence is rated moderate: the T2D association was replicated within the same French study across independent cohorts, and consistent pleiotropic effects on liver fat and vascular phenotypes suggest genuine biological activity at this locus. However, rs767870 has not appeared in the largest T2D GWAS meta-analyses (DIAGRAM, UKBB), likely reflecting its moderate effect size (OR ~1.25) and ~15% MAF, which give it limited power in studies not specifically focused on ADIPOR2.

Practical Actions

For AG and GG carriers, the main levers are those that directly amplify adiponectin signaling or compensate for impaired PPARα induction: omega-3 fatty acids (EPA/DHA) are independent PPARα ligands that partially bypass the receptor step; aerobic exercise robustly raises plasma adiponectin and upregulates ADIPOR2 expression in muscle; and reduced saturated fat intake lowers the ceramide substrate that impaired AdipoR2 ceramidase activity handles less efficiently.

Liver fat monitoring is particularly actionable: serum ALT and gamma-GT provide inexpensive early signals of hepatic fat accumulation that can guide dietary intervention before overt hepatic steatosis develops.

Interactions

ADIPOR2 acts in the same adiponectin signaling axis as ADIPOR1 (rs1044498), which primarily signals through AMPK rather than PPARα. Carriers of risk alleles at both receptors face a doubly attenuated adiponectin response — reduced AMPK activation (AdipoR1) and reduced PPARα induction (AdipoR2) — potentially producing greater combined insulin resistance than either variant alone. A compound action for the combined genotype is warranted if rs1044498 risk alleles are also present.

PPARG rs1801282 (Pro12Ala) is a functional variant in the PPARγ gene that affects adipogenesis and adiponectin secretion upstream of ADIPOR2 signaling. Carriers of the Ala12 (G) allele at rs1801282 tend to have higher circulating adiponectin but greater adipose tissue (more substrate for the receptor). The combined effect of elevated adiponectin (PPARG Ala12) and impaired receptor (ADIPOR2 G allele) has not been characterized in a single published study but represents a plausible pathway interaction for compound action design.